Latest Headlines

  1. Japan Tobacco And D-Wave Announce Quantum Proof-Of-Concept Outperforms Classical Results For LLM Training In Drug Discovery 3/31/2025

    D-Wave Quantum Inc. (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”) today announced the completion of a joint proof-of-concept project that used quantum computing technology and artificial intelligence (AI) in the drug discovery process.

  2. IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation For Darovasertib Monotherapy In Neoadjuvant Uveal Melanoma 3/31/2025

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma (UM) for whom enucleation has been recommended.

  3. FDA Approves Qfitlia (Fitusiran), The First siRNA (RNAi Therapeutic) For The Treatment Of Hemophilia A Or B 3/28/2025

    Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Qfitlia (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds.

  4. Shionogi Submits Supplemental New Drug Application For Ensitrelvir In Japan For The Post-Exposure Prophylaxis Of COVID-19 3/27/2025

    Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) submitted today supplemental New Drug Application (sNDA) in Japan for its investigational, oral antiviral ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622, hereafter “ensitrelvir”) for post-exposure prophylaxis of COVID-19.

  5. Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration 3/27/2025

    Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD).

  6. New Pathways Discovered For Drugs To Act On Cells 3/27/2025

    Previously unknown access points in cell membrane proteins have been discovered, enabling laboratory-developed drugs to modify cell function.

  7. GV20 Therapeutics Announces Collaboration Agreement With Mitsubishi Tanabe Pharma Corporation To Develop Novel Antibody-Drug Conjugates 3/26/2025

    GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC).

  8. A Breakthrough Moment: Mcmaster Researchers Discover New Class Of Antibiotics 3/26/2025

    The last time a new class of antibiotics reached the market was nearly three decades ago — but that could soon change, thanks to a discovery by researchers at McMaster University.

  9. Redwire Awarded NASA Contract To Expand Pharmaceutical Drug Development In Space For Future Commercialization 3/25/2025

    Redwire Corporation, a leader in space infrastructure for the next-generation space economy, has been awarded a NASA contract to launch four additional pharmaceutical drug investigations to the International Space Station using the company’s innovative Pharmaceutical In-space Laboratory (PIL-BOX).

  10. SOLVE FSHD Announces Strategic Collaboration With Transcripta Bio To Advance Drug Discovery For FSHD 3/25/2025

    SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company.